Potential of imaging biomarkers for characterization of renal masses

Lawrentschuk, Nathan; Scott, Andrew M.; Davis, Ian D.

doi:10.1586/era.10.69

Expert Review of Anticancer Therapy

2010

DOI: 10.1586/era.10.69

|View full text |Cite

Potential of imaging biomarkers for characterization of renal masses

Nathan Lawrentschuk

Andrew M. Scott

Ian D. Davis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many other markers used in PET for renal masses. Clinical trials using I‐cG250 have shown promise and may provide improved accuracy when compared with 18F‐FDG PET/CT …”

mentioning

confidence: 99%

An interesting case of F‐18 fluorodeoxyglucose positron emission tomography avid renal oncocytoma

Raman¹,

Campbell

McLeod³

2014

ANZ Journal of Surgery

View full text Add to dashboard Cite

A 68-year-old man presented with a single episode of painless macroscopic haematuria. Initial investigations included upper urinary tract imaging with ultrasound and then computed tomography (CT), and cystoscopic evaluation.Renal ultrasound showed a 22-mm echogenic lesion in the interpolar region of the right kidney, and two lesions in the left kidney -a 57-mm left upper pole echogenic lesion and a 26-mm left interpolar echogenic lesion. A dedicated triple-phase renal CT showed a 55-mm solid, enhancing, endophytic lesion in the upper pole of the left kidney, and a 25-mm enhancing lesion of the interpolar left kidney. In the right kidney, there was a subtle 25-mm lesion in the interpolar renal cortex.Given the complex and bilateral nature of the renal lesions, further evaluation was performed by means of a diethylene-triamine pentaacetate (DTPA) nuclear medicine scan and an F-18 positron emission tomography (PET)/CT scan. DTPA renogram demonstrated normal overall renal function, with a differential function of 48% on the right and 52% on the left. The F-18 PET/CT scan showed moderate uptake in the large renal lesion in the left upper pole and avid uptake in the left interpolar lesion. There was no evidence of fluorodeoxyglucose (FDG) uptake in the right kidney (Figs 1,2). Staging showed no metastatic disease.A laparoscopic left radical nephrectomy was performed, with a plan for radiological surveillance of the small PET negative lesion in the right kidney. Histopathology revealed a 50-mm oncocytoma in

show abstract

“…There are many other markers used in PET for renal masses. Clinical trials using I‐cG250 have shown promise and may provide improved accuracy when compared with 18F‐FDG PET/CT …”

mentioning

confidence: 99%

An interesting case of F‐18 fluorodeoxyglucose positron emission tomography avid renal oncocytoma

Raman¹,

Campbell

McLeod³

2014

ANZ Journal of Surgery

View full text Add to dashboard Cite

show abstract

Active Surveillance: A Potential Strategy for Select Patients with Small Renal Masses

Smaldone

Uzzo²

2011

Future Oncol.

View full text Add to dashboard Cite

Increased abdominal imaging has led to the significant incidental detection of clinically localized renal masses. While the gold standard remains surgical excision, mortality rates from kidney cancer remain relatively unchanged implying that a proportion of small renal masses may be indolent tumors that do not require surgical intervention. As a result, active surveillance has emerged as an alternative management strategy in select patients with significant competing risks. Although the contemporary literature characterizing the natural history of untreated small renal masses is limited, recent data demonstrate that many incidental renal masses demonstrate slow growth kinetics with a low rate of progression to metastatic disease over an intermediate time period. Prospective trials are necessary to define entry and intervention criteria for active surveillance protocols.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Potential of imaging biomarkers for characterization of renal masses

Cited by 2 publications

References 44 publications

An interesting case of F‐18 fluorodeoxyglucose positron emission tomography avid renal oncocytoma

An interesting case of F‐18 fluorodeoxyglucose positron emission tomography avid renal oncocytoma

Active Surveillance: A Potential Strategy for Select Patients with Small Renal Masses

Contact Info

Product

Resources

About